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The  parasitic  disease  malaria  threatens  more  than 3 billion  people  worldwide,  resulting  in  more  than
200 million  clinical  cases  and  almost  600,000  deaths  annually.  Vaccines  remain  crucial  for prevention
and  ultimately  eradication  of  infectious  diseases  and, for malaria,  whole  sporozoite  based  immunization
has  been  shown  to  be the  most  effective  in  experimental  settings.  In  addition  to  immunization  with
radiation-attenuated  sporozoites,  chemoprophylaxis  and  sporozoites  (CPS)  is  a  highly  efﬁcient  strategy
to induce  sterile  protection  in humans.  Genetically  attenuated  parasites  (GAP)  have  demonstrated  signif-
icant protection  in rodent  studies,  and  are  now  being  advanced  into  clinical  testing.  This  review  describesmmunization
porozoite
hemoprophylaxis
hloroquine
enetic attenuation
the  existing  pre-clinical  and  clinical  data on  CPS  and  GAP,  discusses  recent  developments  and  examines
how  to transform  these  immunization  approaches  into  vaccine  candidates  for clinical  development.
©  2015  Elsevier  Ltd. This is an  open  access  article  under  the CC BY  license
(http://creativecommons.org/licenses/by/4.0/).iver stage
re-erythrocytic stages
. Background
Malaria is a life-threatening, multi-organ disease caused by
lood stage infections with Plasmodium parasites, particularly Plas-
odium falciparum.  Disease-limiting immunity that develops after
ultiple malaria episodes does not prevent parasitemia or trans-
ission [1]. WHO  estimates that despite the massive roll-out of
onventional control measures over the last decade, malaria causes
ore than 200 million clinical cases and claims almost 600,000
ives per year, mostly in African children [2]. Further progress
ill necessitate novel interventions that can reliably interrupt the
ransmission cycle and achieve elimination of malaria. A potent and
ong-lasting vaccine is the most promising strategy to achieve this
mbitious goal; however, it has proved difﬁcult to develop [3].
Malaria parasites are unicellular eukaryotes with a complex life
ycle characterized by developmentally distinct phases of rapid
 Open Access provided for this article by the PATH Malaria Vaccine Initiative and
xxonMobil Foundation.
∗ Corresponding author. Tel.: +31 624959093.
E-mail address: else.bijker@radboudumc.nl (E.M. Bijker).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.095
264-410X/© 2015 Elsevier Ltd. This is an open access article under the CC BY license (htand massive asexual replication in the vertebrate host and the
Anopheles vector, linked by short but pronounced population bot-
tlenecks during host transitions. One such bottleneck occurs during
transmission, when female Anopheles mosquitoes inoculate tens
to hundreds of motile sporozoites into the human host. Following
active penetration into the blood circulation, sporozoites are pas-
sively carried to the liver where they rapidly invade hepatocytes.
Within a week, a single, clinically silent round of replication from
a single P. falciparum sporozoite will give rise to 1 × 103 to 5 × 104
invasive forms of the parasite, termed merozoites, which initiate
the pathogenic intra-erythrocytic replication cycle and can result in
up to 1013 parasites at the height of an infection. The small number
of naturally transmitted sporozoites in an injected inoculum may
explain the apparent lack of acquired pre-erythrocytic immunity
even in individuals with substantial anti-blood stage immunity (as
evidenced by recurrent asymptomatic and low-density blood stage
re-infections) [4,5].
Experimental malaria vaccine approaches using live sporozoites
and different strategies to arrest the infection before,  during or
shortly after liver stage development induce immunity target-
ing this clinically silent phase of the Plasmodium life cycle [6].
The concept is simple: deliver attenuated parasites to induce
tp://creativecommons.org/licenses/by/4.0/).
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nti-sporozoite and anti-liver stage immune responses capable of
eliably preventing progression of a subsequent infection beyond
he liver stage and thus completely averting a pathogenic blood
tage infection. Instead of trying to mimic  ‘natural’ immunity
gainst malaria parasites as induced in residents of endemic
reas, whole sporozoite vaccination aims for ‘unnatural’ immu-
ity by induction of effective, sterilizing immune responses [5,7,8].
hile antibodies are important to target the extracellular sporo-
oites, cellular responses are likely to be crucial for elimination
f intracellular liver stages. During differentiation and replication
f liver stages, antigen expression changes signiﬁcantly [9]. In
rief, upon invasion of hepatocytes sporozoites transform inside
 parasite induced cellular compartment (parasitophorous vac-
ole). Parasites then start a process of massive replication, termed
chizogony, at the end of which, thousands of daughter cells
re formed. These cells are differentiated into invasive blood
tage parasites (merozoites) that are released in ‘batches’ into the
lood stream within membranous remnants of their host cells
merosomes). The transformation from sporozoites to merozoites
s driven by the expression of a discrete set of genes, includ-
ng potential antigens. Whole sporozoite immunization therefore
xposes the immune system to a wide array of parasite antigens
s opposed to a single or limited number of antigens used in
ubunit vaccine approaches. This is an advantage because it poten-
ially induces more potent, heterogeneous and broader immune
esponses that can lead to stage- and strain-transcendent immunity
10–13].
There are four approaches to whole organism immuniza-
ion: radiation-attenuated sporozoites (RAS), chemoprophylaxis
nd sporozoites (CPS), genetically attenuated parasites (GAP) and
hemically attenuated parasites. In this review we will discuss
ovel insights and ideas principally on CPS and GAP, whereas RAS
s discussed in more detail elsewhere in this special issue.
. Chemoprophylaxis and sporozoites (CPS)
Administration of sporozoites under chemoprophylaxis as an
mmunization method was ﬁrst explored in rodent malaria models
n the late 1970s–early 1980s using infection under chloroquine
CQ) prophylaxis [14–16]. The rationale is that administration of
ntimalarials with sporozoites allows parasite infection of the
iver but prevents the erythrocytic phase where clinical disease
ccurs. In the case of CPS with CQ, which selectively kills asex-
al blood stage parasites but not sporozoites and liver stage
arasites, the parasite completes liver stage development and
eleases infectious merozoites, which initiate the ﬁrst wave of
lood stages before being eliminated by the drug—exposing the
mmune system to multiple parasite life stages, including those
arasites that either failed to enter or complete liver stage devel-
pment. Though successful in animal models, the efﬁcacy of CPS
n humans was not investigated in clinical trials until 2009 when
0 volunteers were immunized 3 times by the bite of 12–15 P.
alciparum-infected mosquitoes while receiving CQ prophylaxis
17]. This regimen resulted in sterile protection in all 10 vol-
nteers against a controlled human malaria infection (CHMI) by
osquito bites, eight weeks after the ﬁnal immunization [17].
urther, 4/6 of these ‘protected’ volunteers re-challenged at 28
onths post-immunization remained fully protected—indicating
 robust and prolonged immune response [18]. These results have
ecently been conﬁrmed in a follow-up dose de-escalation study,
howing that complete protection is dose-dependent (number of
ites) and have been replicated using meﬂoquine (MQ), a drug
ith similar structure and activity to CQ, with equivalent results
19,20]. Although subjects are exposed transiently to low levels of
lood stage parasitemia during CPS-CQ immunization, protection3 (2015) 7462–7468 7463
in humans appears to be heavily based on pre-erythrocytic immu-
nity [6]. While data from animal models suggest CPS is capable of
eliciting multi-stage immunity, the inability to monitor a continued
parasitemia in human volunteers makes it difﬁcult to examine the
full extent of immunity against blood stage parasites [13,21–24].
Despite being logistically challenging to deliver, the dose of
parasites required to generate immunity similar to RAS is consider-
ably (orders of magnitudes) lower as just 3 × 10−15 mosquito bites
are required for >80% protection [20] compared to the more than
1000 bites required of RAS-infected mosquitoes [25]. These encour-
aging and consistent results have established CPS as the current
benchmark for malaria vaccine development, and have initiated a
large effort to delineate immune mechanisms of protection, to gen-
erate a ﬁrst-generation candidate whole-sporozoite vaccine and to
optimize the CPS immunization regimen.
2.1. Drugs available for CPS
Using drugs targeting blood stages for CPS immunization has
the advantage that full liver stage development can be achieved (as
discussed in more detail later). There are many antimalarial drugs
available that are candidates for CPS. They vary in efﬁcacy, safety
and mechanisms of action but only a handful have been evaluated
in animal or clinical studies for use in CPS.
Drugs that suppress blood stage growth can block infections
during the ﬁrst round of replication inside red blood cells. The
exact mechanism of one such drug, CQ, remains under debate
but most likely acts by disrupting detoxiﬁcation of heme, a
harmful by-product of hemoglobin digestion during the tropho-
zoite phase of blood stage infection [26]. Meﬂoquine (MQ)  is
similar to chloroquine in that it is a quinine derivative and
also kills trophozoites. In order to block blood stage infection
altogether, registered drugs or drug combinations known to
act on replicating Plasmodium liver stages such as primaquine,
sulfadoxine–pyrimethamine, atovaquone–proguanil, doxycycline,
azithromycin and clindamycin (with the exception of primaquine,
all are also potent inhibitors of asexual blood stages) could be used
[27]. Primaquine, pyrimethamine and atovaquone lead to early
developmental arrest, whereas the antibiotics azithromycin, clin-
damycin and presumably, doxycycline allow for an unconstrained
production of merozoites that subsequently fail to complete eryth-
rocytic development, due to loss of apicoplast function [28].
Thus the quiver of antimalarials available for potential use in CPS
is well stocked. Although only CQ and MQ have been demonstrated
effective in humans, alternative protocols have been demonstrated
feasible in murine models using primaquine, pyrimethamine, arte-
sunate, azithromycin, clindamycin and piperaquine [24,29–32].
MQ and CQ were shown to be equally effective in humans [19],
and rodent studies indicate that while CPS with CQ is more potent
than primaquine, antibiotics such as azithromycin induce superior
immunity [31]. These ﬁndings support the hypothesis that full liver
stage development, but not necessarily exposure to blood stages, is
advantageous [33]. These studies not only provide greater options
for clinical development, but may  prove to be essential in under-
standing the immune mechanisms involved in CPS. Overall, the use
of registered drugs with proven chemoprophylactic efﬁcacy for CPS
provides a unique platform for rapidly testing experimental whole-
parasite vaccine approaches. However, in order to advance CPS
from an approach to study anti-malarial immunity into a clinical
intervention, further work will be required (Table 1).3. Genetically attenuated parasites (GAPs)
Parasites can be attenuated by deletion of genes that are neces-
sary at different phases of liver stage developmental progression.
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Table 1
Challenges and suggested lines of research for CPS and GAP.
Challenges Lines of research
CPS
Optimization of the
prophylactic drug protocol
- Direct comparison of different drugs (e.g.
primaquine, pyrimethamine, artesunate,
azithromycin, clindamycin or piperaquine)
for CPS in humans
-  Development of immunization with a
single dose drug regimen
-  Re-assessment of the drug-development
pipeline for novel candidates
Development of a program of
mass administration using
live sporozoite
immunization and drug
cover in malaria endemic
areas
-  Proof-of-concept of CPS with injectable
sporozoites
- Assessment of vaccine efﬁcacy in
endemic areas, and the effect of
pre-existing immunity and/or
(sub-clinical) blood infection
-  Evaluation of the effect of
post-vaccination natural exposure on
vaccine induced immunity
GAP
Ensuring GAPs are
completely attenuated
- Generation of multiple gene deletion
mutant (each gene governing an
independent and essential liver-stage
function)
- Generation of GAPs encoding proteins
(toxins), which when expressed terminate
parasite development in the liver
Optimizing GAP potency - Generation of late arresting GAPs
-  Creating a GAP that re-capitulates the
features of CPS (i.e. arrest immediately
after parasite entry into the blood);
possibly utilizing inducible and/or
auxotrophic systems
General—whole sporozoite
immunization
Elucidation of immune
mechanisms of protection
- Development of functional assays to
evaluate pre-erythrocytic cellular and
humoral immunity in immunized humans
Identiﬁcation of key antigens
and immune modulators of
protection
-  In vitro stimulation of T cells with
synthetically produced overlapping
peptides
- Assessment of IFN production by T cells
to recombinantly expressed or synthetic
Plasmodium proteins (cross-) presented by
autologous monocyte-derived DCs
- Analysis of antibody speciﬁcities by
protein microarrays
- Sequencing of the B cell receptor
repertoire of circulating plasmablasts and
memory B cells after immunization
Generation of strain
transcending immunity and
improvement of durability of
protection
- Immunization using multiple Plasmodium
strains; isolation and characterization of
alternative strains for CHMI and
immunization
-  Optimal dose ﬁnding
Improvement of route of
administration and
- Establish a route of administration most
effective and suitable for use in large
campaigns targeting young children in
malaria endemic countries
Reduction of costs and
improvement of practicality
of whole sporozoite
vaccination
-  Improvement of sporozoite preservation,
alteration of sporozoites; maintain
viability during transport on ice or at room
temperature
-  Establishment of axenic in vitro culture of
sporozoites to eliminate the requirement
for mosquito-based production
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rent transgenic methods) [2]; it cannot have an essential function
in sexual and/or mosquito stage development (otherwise sporo-his attenuation strategy was made possible by the development
f gene deletion methodologies in Plasmodium [34,35], delineation
f the full Plasmodium genome sequence of multiple species and
hrough transcriptional proﬁling. The latter identiﬁed genes that
re differentially up-regulated in sporozoites and liver stages, and
herefore are most likely to be essential for parasite development3 (2015) 7462–7468
through the liver [9,36,37] without having a role in blood stage
replication.
Genetically attenuated parasites (GAP) have demonstrated
substantial to complete attenuation and sustained protective
immunity in rodent malaria studies [38,39]. The ﬁrst clinical study
with a P. falciparum GAP showed considerable but incomplete
attenuation [40], indicating that complete attenuation of the par-
asite in humans remains challenging. While GAP also face the
hurdles concerning production, storage, transport and administra-
tion of other candidate live malaria vaccine approaches such as RAS
and CPS, they potentially offer several beneﬁts.
GAP are parasites with well-characterized genetic changes,
while in RAS the effect of radiation acts upon the parasites’
DNA inducing non-speciﬁc damage that completely prevents par-
asite replication. Knowing the exact genotype allows precise
characterization of the product, and provides manufacturing and
regulatory advantages. Moreover, the timing of parasite arrest can
be controlled in GAP, whereas RAS do not develop beyond the
stage where DNA-replication is required. Consequently, GAPs that
develop further into liver stage development may generate more
potent immune responses. Indeed studies in rodent models with
attenuated parasites have shown that immunization with greater
numbers of parasites or with parasites that progress further into
infection can provide superior immunity than low dose and/or early
arresting parasites [11,33,41]. It has been proposed that late liver-
arresting parasites have the ability to generate a greater quantity
and breadth of antigen exposure that result in stronger and more
robust immune responses capable of protecting against both sporo-
zoite and blood stage challenges in murine models [11]. Equivalent
immune responses are also achieved by CPS, but GAP have the
advantage that they do not require the co-administration of drugs.
Another advantage occurs during the manufacturing process: while
RAS are fully infectious and pathogenic prior to irradiation, GAP
are safe and cannot induce blood stage infection in the production
staff. Finally, GAP may  offer more ﬂexibility in terms of engineer-
ing additional changes into the parasite that may  increase their
potency. Although this could also be done with RAS, RAS stop early
into hepatic development potentially limiting expression of the
introduced genes. Another advantage of GAPs is their precision of
attenuation; for RAS, infected mosquitoes must be irradiated with
a dose strong enough to ensure complete attenuation that is suf-
ﬁcient to ensure no sporozoites progress through to blood stage
development. Too strong a dose of irradiation will kill sporozoites
or render them non-invasive, this in turn would greatly reduce their
ability induce sterile immunity, as they are ineffective at generating
robust T cell-mediated immunity, which is believed to necessary
for sterile immunity [31,42]. However, protocols for irradiation to
produce RAS are well established and in numerous clinical trials no
breakthrough blood infections have been reported.
3.1. Selecting gene candidates for deletion
Two features are critical to the development of a candidate
malaria vaccine consisting of attenuated parasites: ﬁrst and most
importantly it must be safe (i.e. complete attenuation in the liver)
and next it needs to be potent (i.e. generation of strong protec-
tive immunity). Therefore the foremost challenge is the selection
of genes for deletion so that they create GAPs that are completely
blocked in development in the liver.
To be considered a gene candidate for deletion, the gene must
fulﬁll several criteria: The encoded protein [1] cannot be essential
for blood stage replication (otherwise it cannot be deleted by cur-zoites will not be produced); and [3] it must be essential for liver
stage development (otherwise the GAP may  progress to blood stage
cine 3
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nfection), preferably during late stages when additional target
ntigens are expressed and presented at high concentration.
Plasmodium genes that govern sporozoite and/or liver stage
peciﬁc functions were ﬁrst identiﬁed by characterizing mRNA
ranscripts that are differentially expressed in salivary gland sporo-
oites [36,37,43]. Deletion of some of these gene candidates (i.e.
IS3 and UIS4) from the genomes of rodent malaria parasites
esulted in the creation of the ﬁrst GAPs [44,45]. Moreover, immu-
ization with sporozoites lacking expression of these proteins
enerated sterile protective immunity against infectious sporozoite
hallenge in mice. Independently, rodent studies investigating pro-
eins of the Plasmodium 6-Cys protein family revealed that one
ember of this family, P52, was vital for parasite development in
he liver and immunization of mice with sporozoites lacking P52
ould also induce protective immunity [46]. Mutants lacking both
he 6-Cys protein P52 either by itself or in combination with a dele-
ion of the gene encoding the closely related protein, P36, were
mong the ﬁrst GAPs to be created in P. falciparum [47–49]. The
rst phase I safety clinical trial with the p52−/p36−/P. falciparum
AP was conducted in 2008 where volunteers were exposed to
 and then 200 bites from mosquitoes infected with this “double
nockout” parasite. Attenuation appeared complete after exposure
o 5 bites but following 200 bites, 1/6 volunteers became blood
tage positive—indicating substantial but incomplete attenuation
40]. Recently, a newly identiﬁed member of the 6-Cys protein fam-
ly, B9, has also been shown to be critical to parasite development
n the liver and mutants lacking this protein can provoke strong
rotective immunity in rodent models [50,51].
After the initial identiﬁcation of the ﬁrst rodent malaria par-
site GAP, a number of additional gene deletion mutants have
een identiﬁed that are completely or partially attenuated and
nduce protective immunity in mice [39,52]. However, of all the
AP identiﬁed in rodent malaria parasites that could be advanced
s a potential P. falciparum GAP, only mutants lacking the gene sap1
alternatively known as slarp), which encodes a protein involved in
he regulation of transcripts in sporozoites, have been shown to
ully attenuate liver stage development, even at very high sporo-
oite doses (up to 5 × 106 inoculated intravenously) [53–55]. All
ther GAPs carry the risk of breakthrough blood infections depend-
nt on sporozoite dose and mouse strain [39].
Consequently, GAP that are most advanced and currently ready
or clinical evaluation consists of mutants where slarp/sap1 has
een removed in addition to a deletion of one or more of the
-Cys genes from the P. falciparum genome. Speciﬁcally, the P.
alciparum GAPs ‘p52−/p36−/sap1−’ and ‘b9slarp’  have both
een examined in blood stage culture, in mosquitoes, in cul-
ured human hepatocytes and in mice engrafted with human
iver tissue and no evidence for full maturation in the liver was
ound [50,56]. These ﬁndings provide sufﬁcient rationale for clin-
cal testing to evaluate their safety and protective efﬁcacy in
umans.
The current P. falciparum GAPs are expected to arrest early in
epatic development, soon after invasion of hepatocytes by sporo-
oites. However, it has been demonstrated that immunization of
ice with late liver stage-arresting GAP, lacking expression of a
rotein involved in fatty acid synthesis, FabB/F, elicits broader and
ore potent CD8T cell responses when compared to irradiated
early arresting) sporozoites [11]. This elicits superior long-lasting
terile protection against a malaria infection by sporozoite chal-
enge and also generates stage-transcending protection against a
irect blood stage challenge mediated by both T cells and anti-
odies [11,12]. These parasites are believed to present a greater
iversity and load of parasite antigens to the host immune system.
owever, P. falciparum parasites lacking FabB/F expression fail to
roduce sporozoites, and thus are currently not useful for human
mmunization [57].3 (2015) 7462–7468 7465
3.2. Genetic attenuation techniques
The permanent removal of genes from the P. falciparum genome
is a complicated process that has required the targeted integration
of plasmid constructs into the parasite genome by double cross-
over homologous recombination. In order to create P. falciparum
GAPs for human use it is essential that any gene deletion is perma-
nent and that reversion to the wild type genotype (and therefore
phenotype) does not occur. Moreover GAPs must also be free of
the drug-resistance markers that were used to select the deletion
mutants, in order to meet regulatory concerns governing the use of
genetically attenuated organisms as vaccines [50]. The removal of
the drug-resistance markers has been achieved by adapting Cre and
FLP recombinase methodologies, which allow for complete exci-
sion of the marker genes from the gene deletion mutant parasites
[58,59]. These methods were developed in large part to facilitate
the production of a multi-gene deletion candidate GAP for human
use since removal of the selectable marker also makes it simpler
to sequentially delete genes that govern independent biological
processes. This is performed to ensure the GAP is completely (and
multiply) attenuated and is thus safe for use in humans. The current
‘p52−/p36−/sap1−’ and ‘b9slarp’  P. falciparum GAP strains fulﬁll
all these requirements [50,56] and are currently being advanced
into clinical testing.
3.3. Novel strategies for the development of next generation GAP
The creation of a safe and protective GAP with multiple genes
removed from the parasite genome could be considered a ‘ﬁrst
generation’ GAP. A ‘second generation GAP’ may include improve-
ments to increase its immunogenicity, for example, one that arrests
the parasite late into hepatic development and therefore induces
stronger and broader protective immune responses as shown in
rodent malaria models [11]. Another possibility would be to modify
the parasite in such a way  that its growth in culture is dependent
upon a speciﬁc compound (i.e. an auxotroph), but importantly it
is unable to develop in vivo in the absence of the compound. An
example of such a strategy has been described where a mutant
parasite has been generated that lacks a functional apicoplast and
requires the addition of exogenous isopentenyl pyrophosphate for
its survival in culture [60].
Moreover, existing GAPs can be further engineered, as genetic
modiﬁcation also allows for the insertion of genes into the genome
of attenuated parasites that have been modiﬁed to be more
potent. Increasing GAP potency must be directed towards gen-
erating protective immune responses with the lowest number
of parasites/dose and the fewest number of doses to generate
sterile protection. Genes encoding molecules that could enhance
P. falciparum GAP potency could include (i) blood or transmis-
sion/mosquito stage Plasmodium antigens under the control of liver
stage speciﬁc promoters to provide multi-stage immunity against
malaria; (ii) genes that express proteins that could serve as adju-
vants to enhance (CD8+) speciﬁc immune responses against liver
stages; and (iii) genes encoding infection-limiting proteins (such
as toxins) such that the GAP completely arrests late into liver stage
development [61].
4. Chemically attenuated parasitesfor vaccination, sporozoites that have been incubated with cen-
tanamycin, a DNA-binding drug, also induce complete liver-stage
arrest in both Plasmodium berghei and Plasmodium yoelii rodent
models [62,63]. Immunizationwith these sporozoites induces
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FNproducing CD8T cells and sporozoite speciﬁc antibodies;
rotection against both homologous and heterologous parasite
hallenge was shown to be similar to RAS [62,63]. The potential
oxicity of residual centanamycin in humans is a concern, how-
ver it has been suggested that the free drug can be washed
rom the parasites before vaccine delivery and the drug that
s present in treated sporozoites is covalently bound to para-
ite DNA and thus should not be available to modify host DNA
62]. This strategy is currently being evaluated for immunization
ith blood-stage parasites in humans (http://www.anzctr.org.au/
CTRN12614000228684.aspx), but no results have been reported
o far.
. Immune responses induced by whole sporozoite
accination
Whole sporozoite vaccines face difﬁcult hurdles in manufactur-
ng, formulation and administration. However, they are far more
ffective than any alternative method investigated to date. Thus,
here has been great interest in elucidating the immunological
echanisms underpinning sterilizing protection. This information
an then potentially be used in the development and improvement
f subunit vaccine strategies. Both cellular and humoral responses
ppear to play a role in protection induced by live sporozoite based
mmunization, although the relative contribution of each remains
nclear.
Early rodent studies using RAS demonstrated an essential and
redominant role for CD8T cells with a contributing but dis-
ensable role for antibodies [64,65]. However, recent mechanistic
nvestigations into protection by all three whole sporozoite immu-
ization methods have demonstrated a diverse and robust immune
esponse that encompasses both CD8 and CD4T cells as well
s a signiﬁcant contribution from antibodies (reviewed in [41]).
onetheless, CD8T cells are recognized as the main effector cell
n eliciting protection after whole sporozoite immunization. Cyto-
oxic T cells speciﬁc for the major sporozoite surface protein CSP
ave been shown to locate and eliminate infected hepatocytes in
odent malaria models [66]. Although the exact mechanism(s) by
hich CD8T cells carry out this killing is unknown, granzyme B,
erforin and/or IFN appear to be required [41,67,68]. A recent
nalysis of peripheral blood mononuclear cells (PBMCs) from CPS-
mmunized volunteers in a clinical trial designed to elicit partial
rotection also implicated a strong role for cytotoxic T cells [20].
n this study, protection was correlated with CD107a expression (a
arker of cytotoxic cell degranulation) on CD4 cells and granzyme
 expression by CD8T cells [20]. No correlation with IFN expres-
ion was identiﬁed. However, this may  be due to the fact that
BMCs may  not mirror the makeup of liver-resident effector cells
69], which are essential for prolonged protection [70]. Analysis of
BMCs from volunteers immunized with a ﬁrst generation GAP also
emonstrated induction of anti-sporozoite T cell responses, asso-
iated with IFN-production [40]. In agreement with this clinical
ata, interrogation of the T cell responses in animals immunized by
oth GAP and CPS also indicates a critical role for CD8T cells and
FN for protection [11,66,71–73].
Antibodies have historically been considered dispensable for
rotection elicited by whole sporozoite immunization, based on
tudies principally performed in animal models [65,73–76]. How-
ver, these studies utilized sporozoite challenge by intravenous
njection, which bypasses sporozoite passage through the dermis
nd minimizes the effect of antibodies on infection rate [77,78]. In a
ose-escalation clinical trial with iv-administered RAS, protection
n individuals correlated with the ability of serum to inhibit sporo-
oite invasion in vitro [79]. Immunization of volunteers by either CQ
r MQ CPS induces antibodies that recognize both pre-erythrocytic3 (2015) 7462–7468
and erythrocytic antigens but are skewed in speciﬁcity towards
pre-erythrocytic antigens [19,80]. These antibodies are also highly
functional as they are capable of inhibiting sporozoite infection of
hepatocytes both in vitro and in humanized liver-chimeric mice
against P. falciparum challenged via mosquito bite [81]. However,
in the most recent partial-protection clinical trial of CQ-CPS, pro-
tection against mosquito bite challenge was in fact negatively
correlated with anti-CSP antibody titers [82]. Although limited, data
from the initial GAP clinical trial suggests that this immunization
strategy is also able to elicit high titers of anti-parasite antibodies
that are capable of robust inhibition of sporozoite invasion in vitro
[83]. Indeed, recent work investigating the antibody responses to
immunization of mice with a late-arresting GAP indicate that these
antibodies are capable of sterile protection against a mosquito bite
challenge even in the absence of T cells [84]. These antibodies also
cross-react with erythrocytic stages and are capable of mediating
stage-transcending protection against a blood stage challenge [24]
(unpublished data, Stefan Kappe). In conclusion, the role of antibod-
ies in whole sporozoite-induced protection is complex and seems
to depend on the experimental system. Analysis of several ongo-
ing trials may  shed some more light on their protective role in
humans.
6. Translating experimental whole sporozoite
immunization approaches to vaccines
The translation of results derived from pre-clinical and clini-
cal whole sporozoite immunization studies into a vaccine, faces
considerable regulatory, manufacturing and technical challenges.
Infected mosquito bite immunization is a powerful and versatile
experimental tool for ﬁrst-in-man studies but cannot be used for
immunizing large numbers of individuals or whole populations.
Therefore, future CPS or GAP vaccination will need to be per-
formed by needle and syringe. Recently, GMP-compliant methods
that meet all regulatory standards to generate and store sterile,
cryopreserved and infectious P. falciparum sporozoites ready for
use in humans have been established by Sanaria Inc., a US-based
company [85]. Studies in humans, using puriﬁed and cryopres-
erved RAS delivered into the skin and subcutaneously by needle
induced suboptimal immune responses and failed to protect vol-
unteers against infectious malaria challenge [69]. In contrast, direct
intravenous inoculation provided complete protective immunity
after 5 rounds of immunization with 1.35 × 105 RAS [79]. Cur-
rently, several trials are ongoing in the US, Europe and Africa to
assess the effect of different immunization schedules and doses on
protective efﬁcacy (against homologous and heterologous CHMI
as well as naturally acquired infection) as well as safety, toler-
ability and practicability of intravenous injection of sporozoites
for CPS and immunization with RAS (please see the article on
GMP-compliant whole sporozoite vaccines in this special issue for
more details [Richie et al.])”. Optimizing the methods of sporozoite
manufacturing, cryopreservation, formulation and administration
is needed for whole sporozoite vaccine approaches, and requires
attention by researchers and funding agencies. One possible way
to improve effective immunization would be the co-administration
of molecules that facilitate parasite entry into the blood or the
use of adjuvants that enhance immunogenicity. For example, -
galactosylceramide, a natural killer T cell ligand, was  shown to
increase protective efﬁcacy of RAS in a rodent model [86].
Another potentially transformative development is the develop-
ment of an in vitro method of cultivating P. falciparum sporozoites.
This would remove both the requirement for, and hand-dissection
of mosquitoes for sporozoite harvest and could greatly ease the
scale-up of sporozoite production—considerably reducing the cost
of sporozoite-based vaccines.
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. Conclusions and future perspectives
The availability of GMP-grade, cryopreserved P. falciparum
porozoites for use in humans has ignited a series of studies that
romise to move protocols quickly from phase I to phase II trials
n both naïve and semi-immune volunteers and hence, closer to a
otential ﬁrst-generation product. Key milestones for future CPS and
AP studies will be (i) demonstration of heterologous protection,
ii) development of practicable regimens with injectable sporo-
oites and (iii) safety with regard to 100% prevention of potentially
ife-threatening breakthrough infections. For CPS the design of a
rug regimen that supports single dose, simultaneous administra-
ion of both parasite inoculum and drug is also paramount. For GAP
accines, the identiﬁcation of Plasmodium genes that are critical to
id-late liver stage development and hence, the creation of late
rresting P. falciparum GAP that are signiﬁcantly more potent than
arly arresting GAPs would be a major improvement [9,52,87–89].
mproving the route of live-sporozoite vaccine administration is
ecessary for both CPS and GAP vaccines.
To meet the challenges of mass vaccination in countries where
alaria is endemic it is necessary that any malaria-vaccine, in par-
icular a live-attenuated vaccine, is safe, affordable, convenient
minimizing the number of immunizations) and it needs to gen-
rate long-lasting strain-transcending protective immunity [3,90].
hile the logistical hurdles involved in delivering a live sporozoite
accine are considerable, experimental whole sporozoite immu-
ization regimens remain by far the most potent malaria vaccine
odalities to date. Thus, in parallel with efforts to pursue licen-
ure and delivery, careful investigation of the immune mechanisms
rom which they derive their potency is critical as it will direct the
ational design of the next generation malaria vaccines.
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